drugset / Trial / NCT07606664

Fezolinetant and Vascular Health and Brain Health

NCT07606664

RandomizedParallel-groupTriple-blindTreatment

Summary

The goal of this clinical trial is to learn whether a study drug called fezolinetant impacts cardiovascular and cognitive health in women who have moderate to severe menopausal hot flashes and night sweats. Researchers will compare fezolinetant to a placebo. A placebo is a pill that looks like the study drug but does not contain any active medicine. This comparison helps researchers understand whether fezolinetant works better than no treatment. Participants will: Be randomly assigned to take either fezolinetant (45 mg) or a placebo once a day for 12 weeks. Visit the research clinic for regular checkups and tests during the study. Complete tests that measure blood vessel function and cognition. Participants and study staff will not know which treatment each participant receives during the study.

Timeline

Start
2026-09-25
Primary completion
2029-11-30
Completion
2029-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Fezolinetant Small molecule 45 mg Oral

Indications